GSK (LON:GSK) Announces Quarterly Earnings Results

GSK (LON:GSK) issued its quarterly earnings results on Wednesday. The company reported GBX 23.20 ($0.29) EPS for the quarter, Digital Look Earnings reports. GSK had a net margin of 12.83% and a return on equity of 33.30%.

GSK Price Performance

GSK stock opened at GBX 1,454.28 ($18.09) on Friday. The stock has a market capitalization of £59.33 billion, a price-to-earnings ratio of 1,286.97, a PEG ratio of 1.24 and a beta of 0.31. The firm’s 50-day moving average price is GBX 1,356.75 and its two-hundred day moving average price is GBX 1,457.45. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. GSK has a 12-month low of GBX 1,282.50 ($15.95) and a 12-month high of GBX 1,823.50 ($22.68).

Wall Street Analyst Weigh In

Several analysts have weighed in on GSK shares. Berenberg Bank lowered their price target on shares of GSK from GBX 1,820 ($22.63) to GBX 1,600 ($19.90) and set a “buy” rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.46).

Insider Transactions at GSK

In related news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction on Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.35) per share, with a total value of £19,725 ($24,530.53). 1.61% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.